摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3-苯并噻二唑-5-羧酸 | 192948-09-7

中文名称
1,2,3-苯并噻二唑-5-羧酸
中文别名
苯并-1,2,3-噻二唑-5-羧酸
英文名称
benzo-1,2,3-thiadiazole-5-carboxylic acid
英文别名
benzo[d][1,2,3]thiadiazole-5-carboxylic acid;benzo[1,2,3]thiadiazole-5-carboxylic acid;1,2,3-Benzothiadiazole-5-carboxylic acid
1,2,3-苯并噻二唑-5-羧酸化学式
CAS
192948-09-7
化学式
C7H4N2O2S
mdl
MFCD01570552
分子量
180.187
InChiKey
OUIALVLMUYKKKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    221-225°C
  • 沸点:
    385.2±34.0 °C(Predicted)
  • 密度:
    1.608±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    91.3
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S24/25
  • 海关编码:
    2934999090

SDS

SDS:14b4121952e4d8a4f507e9a798e429c5
查看
Name: 1 2 3-Benzothiadiazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS: 192948-09-7
Section 1 - Chemical Product MSDS Name:1 2 3-Benzothiadiazole-5-carboxylic acid 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
192948-09-7 1,2,3-Benzothiadiazole-5-carboxylic ac 97% unlisted
Hazard Symbols: None Listed.
Risk Phrases: None Listed.

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 192948-09-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: slight pink
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 221 - 225 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H4N2O2S
Molecular Weight: 180.19

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 192948-09-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,2,3-Benzothiadiazole-5-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 192948-09-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 192948-09-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 192948-09-7 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,2,3-苯并噻二唑-5-羧酸三乙胺氯甲酸异丁酯 、 sodium tetrahydroborate 、 作用下, 以 四氢呋喃 为溶剂, 反应 0.75h, 以56%的产率得到1,2,3-苯并噻二唑-5-甲醇
    参考文献:
    名称:
    [EN] NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS
    [FR] HETEROCYCLES BICYCLIQUES CONTENANT DE L'AZOTE ET UTILISES COMME PRODUITS ANTIBACTERIENS
    摘要:
    环己烷和环己烯衍生物及其在哺乳动物,特别是人类细菌感染治疗方法中有用的药用可接受衍生物。
    公开号:
    WO2003087098A1
  • 作为产物:
    描述:
    1,2,3-苯并噻二唑-5-羧酸甲酯 在 lithium hydroxide monohydrate 、 作用下, 以 四氢呋喃甲醇 为溶剂, 以1.82 g的产率得到1,2,3-苯并噻二唑-5-羧酸
    参考文献:
    名称:
    [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    [FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS D'IMMUNODÉFICIENCE HUMAINE
    摘要:
    公式I-VI的化合物,包括其药用可接受的盐,以及用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法。公式I如下所示:公式(i)
    公开号:
    WO2016172425A1
点击查看最新优质反应信息

文献信息

  • Tetronic and tetramic acids
    申请人:Godel Thierry
    公开号:US20050119329A1
    公开(公告)日:2005-06-02
    This invention relates to new tetronic and tetramic acid derivatives with beta-secretase inhibitory activity of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 6 and R 6′ are as defined hereinabove, to processes for their preparation, compositions containing said tetronic and tetramic acid derivatives and their use in the treatment and prevention of diseases modulated by an inhibitor of β-secretase, such as Alzheimer's disease.
    这项发明涉及具有β-分泌酶抑制活性的新四元和四酰胺衍生物的化学式I: 其中R1、R2、R3、R4、R5、R5'、R6和R6'如上所定义,以及它们的制备过程、含有所述四元和四酰胺衍生物的组合物以及它们在治疗和预防由β-分泌酶抑制剂调节的疾病中的用途,如阿尔茨海默病。
  • Substituted Indoles
    申请人:AbbVie Inc.
    公开号:US20170174688A1
    公开(公告)日:2017-06-22
    The invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    该发明提供了以下式(I)的化合物 其中R 1 ,R 2 ,R 3 ,R 4 ,R 5 和R 6 具有规范中定义的任何值,以及其药学上可接受的盐,这些化合物在治疗由SUV420H1介导和调节的疾病和症状中作为药剂是有用的。还提供了由一个或多个式(I)化合物组成的药物组合物。
  • Kinase Inhibitors
    申请人:Wurster A. Julie
    公开号:US20070032478A1
    公开(公告)日:2007-02-08
    The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    本发明涉及有机分子,能够调节酪氨酸激酶信号传导,以调节、调控和/或抑制异常细胞增殖。
  • Chemical compounds
    申请人:——
    公开号:US20020077337A1
    公开(公告)日:2002-06-20
    The present invention provides a compound of a formula (I): 1 wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    本发明提供了一个式(I)的化合物: 1 其中变量在此处定义;用于制备这种化合物的方法;以及在治疗化学因子(如CCR3)或H1介导的疾病状态中使用这种化合物。
  • Pyridyl inhibitors of hedgehog signalling
    申请人:Gunzner L. Janet
    公开号:US20060063779A1
    公开(公告)日:2006-03-23
    The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R 1 , R 2 , R 3 , R 4 , m and n are as described herein.
    这项发明提供了一种新型的刺刺信号抑制剂,可用作治疗恶性肿瘤的治疗剂,其中化合物具有一般式I: 其中A、X、Y、R1、R2、R3、R4、m和n如本文所述。
查看更多

同类化合物

(5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 阿拉酸式苯-S-甲基 阿拉酸式苯 试剂4,7-Bis(5-bromo-2-thienyl)-5,6-bis(dodecyloxy)-2,1,3-benzothiadiazole 苯并恶唑-6-胺 苯并[d][1,2,3]噻二唑-6-羧酸 苯并[C][1,2,5]噻二唑-5-硼酸频那醇酯 苯并[C][1,2,5]噻二唑-4-磺酸钠 苯并[C][1,2,5]噻二唑-4-基甲醇 苯并[C][1,2,5]噻二唑-4,7-二基二硼酸 苯并[1,2,5]噻二唑-4-羧酸 苯并[1,2,5]噻二唑-4-磺酰氯 苯并[1,2,3]噻二唑-7-基胺 苯并[1,2,3]噻二唑-6-羧酸甲酯 苯并[1,2,3]噻二唑-5-基胺 苯并[1,2,3]噻二唑-4-基胺 苯2,1,3-噻重氮-5-羧酸酯 碘化(2,1,3-苯并硫杂(SIV)二唑-5-基)二甲基八氧代甲基铵 硫代磷酸S-[(2,1,3-苯并噻二唑-5-基)甲基]酯O,O-二钠盐 盐酸替扎尼定-d4 盐酸替扎尼定 灭草荒 替托尼定D4 替扎尼定杂质1 替扎尼定 噻唑并[4,5-f]-2,1,3-苯并噻二唑,6-甲基-(6CI,8CI) 去氢替扎尼定 全氟苯并[c][1,2,5]噻二唑 [7-[2-[2-(8-硫杂-7,9-二氮杂双环[4.3.0]壬-3,5,9-三烯-7-基)乙基二巯基]乙基]-8-硫杂-7,9-二氮杂双环[4.3.0]壬-3,5,9-三烯-2-基]甲胺 N-甲氧基-N-甲基-2,1,3-苯并噻二唑-5-酰胺 N-(5-氯-2,1,3-苯并噻二唑-4-基)硫脲 N,N'-二硫代二(亚乙基)二(2,1,3-苯并噻二唑-5-甲胺) N'-2,1,3-苯并噻二唑-4-基-N,N-二甲基酰亚胺基甲酰胺 BTQBT(升华提纯) 7H-咪唑并[4,5-g][1,2,3]苯并噻二唑 7H-咪唑并[4,5-e][1,2,3]苯并噻二唑 7-肼基[1,3]噻唑并[4,5-e][2,1,3]苯并噻二唑 7-硝基-苯并[1,2,5]噻二唑-4-基胺 7-硝基-1,2,3-苯并噻二唑 7-甲基[1,3]噻唑并[5,4-e][2,1,3]苯并噻二唑 7-甲基[1,3]噻唑并[4,5-e][2,1,3]苯并噻二唑 7-甲基[1,3]噻唑并[4,5-e][1,2,3]苯并噻二唑 7-溴苯并[c][1,2,5]噻二唑-4-磺酸 7-溴-苯并[D][1,2,3]噻二唑 7-溴-5-甲基-4-硝基-2,1,3-苯并噻二唑 7-溴-4-醛基苯并[C][1,2,5]噻二唑 7-溴-2,1,3-苯并噻二唑-4-磺酰氯 7-溴-2,1,3-苯并噻二唑-4-甲腈 7-溴-2,1,3-苯并噻二唑-4-亚磺酸 7-氯-苯并[1,2,5]噻二唑-4-基胺